Beijing Business Daily reporter Dong Liang Ding Ning
Another nucleic acid testing institution in Beijing was investigated!On May 29, according to Ping An Beijing's official Weibo news, Beijing Zhongtong Lanbo Medical Laboratory was suspected of violating the law during the nucleic acid testing process. At present, the Beijing police have filed a case for investigation of the laboratory, and its legal representative Zhang Moumou has been arrested. etc. to be found.Tianyancha shows that Beijing Zhongtong Lanbo Medical Laboratory Co., Ltd. (hereinafter referred to as "Zhongtong Lanbo") is 100% controlled by China Tongfu, a Hong Kong-listed company, and the legal representative of Zhongtong Lanbo is Zhang Huobing.Zhang Huobing is also deeply bound to China Tongfu, and also serves as the legal representative of another holding subsidiary of China Tongfu.It is reported that China Tongfu is currently planning to be listed on the Science and Technology Innovation Board. Industry insiders said that it is unknown whether the negative news will affect the company's return to A process, but it is certain that the news will greatly affect the company's image.
100% owned by China Tongfu
On May 29, according to a report from Ping An Beijing, Zhongtong Lanbo was placed on file for investigation on suspicion of illegal crimes. This is the third nucleic acid testing institution in Beijing to be investigated recently.
Ping An Beijing stated that in order to effectively protect the lives and health of the people and serve the overall situation of the city's epidemic prevention work, the Health and Health Commission, together with market supervision, public security and other departments, continue to conduct supervision and inspections of nucleic acid testing institutions in the city.On May 28, it was found that Zhongtong Lanbo was suspected of violating the law during the nucleic acid testing process.At present, the Beijing police have opened a case for investigation of the laboratory, and the legal representative Zhang Moumou (male, 52 years old) and others have been seized, and the case is under further work.
At the 349th press conference on the prevention and control of the new coronavirus pneumonia in Beijing on May 29, the above incident was further explained.According to preliminary investigation, in order to save costs and speed up the schedule, the company has seriously violated the new coronavirus nucleic acid detection operation specifications. Even though it knew that excessive mixed testing might lead to inaccurate test results, it still adopted the method of multi-tube mixed testing for testing. , suspected of obstructing the prevention and treatment of infectious diseases.
According to the data, Zhongtong Lanbo is a medical entity integrating clinical inspection services, clinical experiments, scientific research and development.According to Tianyan Check, Zhongtong Lanbo also has three subsidiaries: Hefei Zhonghe Zhongtong Lanbo Medical Laboratory Co., Ltd., Wuhan Zhonghe Zhongtong Lanbo Medical Laboratory Co., Ltd., and Zhonghe Zhongtong Lanbo (Chengdu) Medical Laboratory Co., Ltd. The holding subsidiary is engaged in related testing activities in Hefei, Wuhan and Chengdu.
On the evening of May 29, according to the "Hefei Release" WeChat public account, after the information was released, Hefei City took quick action to start inspections at the company's nucleic acid testing agency in Hefei, and conduct a comprehensive inspection and review of the retained samples.As of 17:50 that day, no abnormality was found.In order to do the relevant work in a more detailed and stable manner, the company's testing services in Hefei will be suspended.After the comprehensive inspection is completed, it will be resumed as the case may be.
A reporter from Beijing Business Daily found that Zhongtong Lanbo has a great background, and the company is 100% controlled by China Tongfu, a Hong Kong-listed company.Its legal representative, Zhang Huobing, also serves as the legal representative of Beijing Northern Biotechnology Research Institute Co., Ltd., another holding subsidiary of China Tongfu.In addition, Zhang Huobing also serves as a director of two companies in which China Tongfu holds shares. It can be seen that Zhang Huobing has a deep relationship with China Tongfu.
It is worth mentioning that this is the third nucleic acid testing institution in Beijing to be investigated recently. Previously, Park Shi Medical Laboratory and Beijing Jinzhun Medical Laboratory Co., Ltd. check.The legal representative of Jinzhun Medical, Wang Xuegang, is a director of the A-share listed company Baipsis.
In response, Baipsis responded that Wang Xuegang is an external director of the company, does not hold other positions other than director, and does not participate in the daily operation and management of the company.At present, the company's operation is normal, and this matter has no impact on the company's production and operation, financial status and solvency.In addition, except that Wang Xuegang is the legal representative of Jinzhun Medical, the company has no other related relationship with Jinzhun Medical, and the company has no daily business relationship with Jinzhun Medical and Wang Xuegang.
The controlling shareholder plans to be listed on the Science and Technology Innovation Board
It is understood that China Tongfu is currently planning to return to A shares and plan to land on the Shanghai Stock Exchange's Science and Technology Innovation Board.
Back in time to January 29, 2021, China Tongfu announced that the company's board of directors approved the initiation of the proposed issuance of A-shares and listing on the Shanghai Stock Exchange's Science and Technology Innovation Board.
It is reported that the matter is currently in the approval process of the State-owned Assets Supervision and Administration Commission.In addition, at the 2021 performance briefing held by China Tongfu recently, China Tongfu stated that the company will accelerate the issuance and listing of the A-share science and technology innovation board, raise development funds, optimize the financing structure, and enhance market competitiveness.
It is understood that China Tongfu is approved by the State-owned Assets Supervision and Administration Commission and the Ministry of Finance, jointly funded by China National Nuclear Corporation, China Institute of Atomic Energy and China Nuclear Power Research and Design Institute, and built on the platform of the former China Isotope Co., Ltd. Technology application industry specialized company.
China Tongfu was listed on the main board of the Hong Kong Stock Exchange in 2018. The company is mainly engaged in isotope products and irradiation processing. It is the largest radiopharmaceutical for imaging diagnosis and treatment in China, urea breath test kits and testers, medical and Supplier of industrial radioactive source products.
Behind the plan to return to A, China Tongfu's 2021 performance is gratifying.Financial data shows that in 2021, China Tongfu will achieve an operating income of about 5.144 billion yuan, a year-on-year increase of 20.3%; the corresponding attributable net profit achieved is about 336 million yuan, a year-on-year increase of 57.2%.In addition, during the reporting period, China Tongfu’s independent medical laboratory services realized revenue of 228 million yuan, a year-on-year increase of 77%.
How do you view China's co-radiation A plan?Will the investigation of the subsidiary affect the company's return to A?Economist Song Qinghui said in an interview with the Beijing Business Daily that the company plans to return to A, or in order to obtain a better valuation than Hong Kong stocks, adding a new financing channel to facilitate the participation of domestic investors.At a time when the responsibility for epidemic prevention and control is heavy, this incident may have a direct and significant impact on the listed company, which may affect its planning to return to the A process.
In the opinion of investment and financing expert Xu Xiaoheng, it is currently unknown whether the negative news will affect the listed company's return to A, but it is certain that the news will greatly affect the image of the listed company.
In addition, China Tongfu is also the controlling shareholder of Atomic Hi-Tech, a company listed on the New Third Board. The main products of Atomic Hi-Tech are radiopharmaceuticals, radioactive sources, radioactive medical devices, radiolabeled compounds and tracers.In 2021, Atomic Hi-Tech will achieve an operating income of about 1.325 billion yuan, and the corresponding attributable net profit will be about 268 million yuan, which is an important source of profit for China Tongfu.
As of the close on May 27, China Tongfu reported HK$19.38 per share, with a total market value of HK$6.199 billion.
In response to the company-related issues, a reporter from Beijing Business Daily called the China Tongfu Investor Line for an interview, but no one answered the phone.
